{"summary": "the first aim of this study was to develop a novel inactivated porcine epidemic diarrhea virus vaccine using the recently isolated Korean PEDV QIAP1401 strain. the second was to determine the optimum adjuvant formulation of the inactivated PEDV vaccine that induces protection against viral challenge. the disease is highly contagious and lethal in piglets. it is characterized by clinical signs such as diarrhea, vomiting, anorexia, and dehydration. the disease is characterized by clinical signs such as diarrhea, vomiting, anorexia, and dehydration, with high mortality in neonatal piglets. severe PED epidemics have occurred in many swine-producing countries. since 2010, severe PED epidemics have occurred in many swine-producing countries. recent severe PED epidemics have emphasized importance of establishing effective disease prevention nationwide. AP1401, isolated in our laboratory, was propagated on vero cells. it was used after 70 passages (QIAP1401-p70) for viral infection, confluent monolayers were washed with phosphate-buffered saline. the whole genome sequence was compared with those of the following PEDV reference strains isolated in the united states. the vaccines PEDV QIAP1401-p70 was chemically inactivated using binary ethyleneimine (BEI) adjuvants to beI-inactivated viral fluid to final adjuvant concentrations of 30% and 10% (v/v), followed by vortexing at room temperature for 15 minutes. all adjuvanted vaccines contained 0.01% of thimerosal to prevent growth of microorganisms, and were aseptically transferred to sterile vaccine vials. serum samples collected from the pigs after vaccination and challenge were diluted twofold (1:4 to 1:512) in serum-free DMEM containing 1 g/mL trypsin and mixed with an equal volume of a virus suspension containing 100\u2013200 TCID50/0.1 mL PEDV. after incubation for 48 hours, 200 L of the virus-serum mixture were added to confluent Vero cell monolayers. viral RNA template was added to 20 L real-time reverse transcription polymerase chain reaction (rRT-PCR) master mix from the powerChek PEDV real-time RT-PCR kit. reactions were run in presence/absence mode on the Applied Biosystems 7500 Fast Real-Time PCR System. the results were analyzed by the StepOne Plus v2.3 software. washed with phosphate-buffered saline (PBS) and inoculated with the PEDV isolate at a 0.1 multiplicity of infection in DMEM's modified Eagle's medium. after incubation for 1 hour at 37\u00b0C in an atmosphere of 5% CO2 the culture medium was replaced to remove extracellular virions. experimental vaccines were prepared by mixing beI-inactivated PEDV QIAP1401-p70 with a commercial adjuvant according to manufacturers' recommendations. ISA201 and ISA206 are oil-based multiphasic-emulsion adjuvants, and ISA206 are aqueous adjuvants. all adjuvanted vaccines contained 0.01% of thimerosal to prevent growth of microorganisms. all adjuvanted vaccines were aseptically transferred to sterile vaccine vials. after 1 week of acclimatization, pigs were randomly divided into four vaccination groups. serum samples collected from the pigs after vaccination and challenge were diluted twofold (1:4 to 1:512) in serum-free DMEM containing 1 g/mL trypsin and mixed with an equal volume of a virus suspension containing 100\u2013200 TCID50/0.1 mL PEDV. the cultures were washed three times with PBS containing 1 g/mL trypsin and replenished with viral growth medium. the reactions were run in presence/absence mode on the Applied Biosystems 7500 Fast Real-Time PCR System at 50\u00b0C for 30 minutes, 95\u00b0C for 10 minutes, and then 40 cycles of 95\u00b0C for 15 seconds and 60\u00b0C for 1 minute. the results were analyzed by the StepOne Plus v2.3 software (Applied Biosystems) we identified 42 amino acid (aa) mutations in the ORF1a gene of the QIAP1401-p70 isolate. the deletion mutant emerged after 41 sequential passages. the deletion mutant was present during the following three passages. non-vaccinated control (NVC) group exhibited early signs of disease, typically mild diarrhea and loss of appetite (mean clinical score 1.0) the ISA206-adjuvanted vaccine group exhibited weaker and delayed clinical signs, mainly mild diarrhea (mean clinical score 1.0) in the ISA201 vaccine group, clinical disease progression was slow, and clinical severity was relatively weak, but watery diarrhea eventually developed. the viral shedding rates differed significantly among the groups. serum antibody response was assessed by I-ELISA and VN. all vaccines induced a significant PEDV-specific serum IgG response to PEDV. DV-specific IgG and virus-neutralizing antibody titers indicate significant differences from the non-vaccinated control (NVC) group. different lower-case letters above the bars indicate significant differences between the groups. the whole genome of the PEDV USA/Minnesota250/2014 strain was used as a reference for sequencing because of its close genetic relationship to QIAP1401 isolates. however, we identified 42 amino acid (aa) mutations, including a 25 aa deletion in the ORF1a gene of the QIAP1401-p70 isolate. clinical assessments All growing pigs were apparently healthy and had no clinical symptoms before oral challenge. the protective efficacy of the experimental vaccines against challenge with virulent homologous virus was determined by the absence of clinical signs and decreased viral shedding in feces. PEDV RNA was first detected in one of four pigs in the IMS1313, IMSgel, and NVC groups at 3 dpc. viral shedding in feces continued for 3 and 6 days, respectively. in the other vaccinated groups and in the NVC group, viral shedding in feces was observed until the end of the challenge experiment. Pigs were vaccinated at 2-week intervals and then challenged with virulent homologous virus (porcine epidemic diarrhea virus [PEDV] OIAP1401-p11) serum samples collected at 0, 14, 28, and 48 days post-vaccination were subjected to enzyme-linked immunosorbent assay (ELISA) and virus neutralization (VN) test (C and D) of PEDV-specific IgG and virus-neutralizing antibody titers. ISA206 and ISA201 adjuvants induce a virus-neutralizing antibody response more rapidly than the IMS1313 and IMSgel adjuvants. most PEDV strains associated with recent severe PED outbreaks were of the G2b genogroup. this isolate is almost genetically identical to the PEDV strains responsible for the severe PED epidemics in Asia and the United States since 2013. e study in which growing pigs were vaccinated with 106.0 to 108.0 TCID50/mL inactivated PEDV vaccine reported that the humoral immune response increased with an increase in the viral titer inoculated. adapted viral variants that yield higher titers should be used in the development of inactivated viral vaccines. pigs of all ages are susceptible to PEDV infection. emulsified adjuvants are commonly used in veterinary vaccines. emulsified adjuvants are composed of nanoparticles and polymers. a novel inactivated PEDV vaccine formulated with a W/O/W emulsion adjuvant was immunogenic and effective in growing pigs. our results may be used to reduce the risk of failure in future clinical trials of PEDV vaccines."}